Get the Stockscreener App
102.87
0.48%
0.49
After Hours:
102.90
0.03
+0.03%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $102.87, with a volume of 5.43M.
It is up +0.48% in the last 24 hours and down -9.86% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$102.38
Open:
$102.02
24h Volume:
5.43M
Relative Volume:
0.50
Market Cap:
$178.75B
Revenue:
$44.33B
Net Income/Loss:
$6.50B
P/E Ratio:
27.68
EPS:
3.717
Net Cash Flow:
$7.40B
1W Performance:
-1.63%
1M Performance:
-9.86%
6M Performance:
-22.65%
1Y Performance:
-22.03%
1-Day Range:
$101.55
$103.47
1-Week Range:
$100.88
$105.46
52-Week Range:
$100.88
$139.06
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
102.87 | 178.75B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
331.54 | 126.97B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.63 | 111.22B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.82 | 93.36B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.05 | 46.73B | 6.07B | 1.06B | 1.34B | 1.8063 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Exact Sciences Corp. stock: Acquired by Abbott – What it means for you now - ad-hoc-news.de
Erste Group Keeps Their Hold Rating on Abbott Laboratories (ABT) - theglobeandmail.com
Abbott Stock Sits 26% Off Its Peak While Analysts Back a $132 Mean Price Target - TIKR.com
Analysts’ Top Healthcare Picks: Abbott Laboratories (ABT), Cogent Biosciences (COGT) - theglobeandmail.com
Molecular Diagnostics Market Size is Expected to Reach USD 43.50 Billion by 2035 Owing to the Surging Demand for Accurate and Early Disease Detection Globally | SNS Insider - GlobeNewswire Inc.
Aberdeen Group plc Increases Holdings in Abbott Laboratories $ABT - marketbeat.com
Abbott India Ltd Stock: A Stable Player in India's Booming Healthcare Sector for Long-Term Investors - AD HOC NEWS
What Abbott Laboratories (ABT)'s Oncology Test Integration Into OncoEMR Means For Shareholders - simplywall.st
Abbott Laboratories (ABT) director receives 382 stock equivalent units as fees - Stock Titan
Director at Abbott (NYSE: ABT) receives stock equivalent unit award - Stock Titan
Abbott (ABT) director Gonzalez receives 321 stock equivalent units as fees - Stock Titan
Abbott (ABT) director Robert Alpern awarded 76 stock equivalent units as fees - Stock Titan
Abbott Laboratories (ABT) director Nita Ahuja granted 102 stock equivalent units - Stock Titan
Sinocare Can't Scrap Abbott's Glucose Monitor Ban At UPC - Law360
ABT SEC FilingsAbbott Labs 10-K, 10-Q, 8-K Forms - stocktitan.net
Compagnie Lombard Odier SCmA Makes New Investment in Abbott Laboratories $ABT - marketbeat.com
Abbott India Ltd Stock: Steady Growth in India's Pharmaceutical Sector Amid Evolving Healthcare Dema - AD HOC NEWS
Bank Pictet & Cie Europe AG Decreases Position in Abbott Laboratories $ABT - marketbeat.com
Banque Pictet & Cie SA Sells 83,130 Shares of Abbott Laboratories $ABT - marketbeat.com
Drug Delivery Device Market Is Booming Worldwide 2026-2033 | - openpr.com
Abbott Laboratories Expands into Wearable Technology Through Whoop Investment - AD HOC NEWS
Abbott’s Whoop Investment Puts Digital Health Wearables On Shareholders’ Radar - Yahoo Finance
Assessing Abbott Laboratories (ABT) Valuation After New Flatiron Health Oncology Integration - simplywall.st
Abbott joins $575M funding round for wearable maker Whoop - MassDevice
Abbott: A Brighter Investment Case Heading Into Q1 Earnings (Rating Upgrade) (NYSE:ABT) - Seeking Alpha
Reasons to Retain Abbott Stock in Your Portfolio Now - TradingView
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock - Yahoo Finance
20,751 Shares in Abbott Laboratories $ABT Bought by Shrier Wealth Management LLC - marketbeat.com
Abbott Laboratories Pakistan : Change in Date and Time of the 77th Annual General Meeting - MarketScreener
Whoop raises $575M—Abbott, LeBron James, Cristiano Ronaldo among the investors - cardiovascularbusiness.com
Abbott Oncology Integration Into OncoEMR Tests Long Term Growth Story - simplywall.st
Whoop raises $575M, adds Abbott as strategic investor - medtechdive.com
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Abbott Laboratories (ABT) - The Globe and Mail
Abbott integrates Precision Oncology portfolio into Flatiron’s OncoEMR - Yahoo Finance
BTIG Research Lowers Abbott Laboratories (NYSE:ABT) Price Target to $131.00 - marketbeat.com
BTIG Research Adjusts Abbott Laboratories PT to $131 From $140, Maintains Buy Rating - MarketScreener
Whoop Raises $575M at $10.1B Valuation, Abbott Joins as Investor - Athletech News
Abbott Laboratories $ABT Position Trimmed by J. Safra Sarasin Holding AG - marketbeat.com
Abbott Laboratories $ABT Shares Bought by Mn Services Vermogensbeheer B.V. - marketbeat.com
Abbott (ABT) Enhances Cancer Care with OncoEMR Test Integration - GuruFocus
Abbott (ABT) Dips More Than Broader Market: What You Should Know - Yahoo Finance Australia
Dairy industry consolidation | Lactalis, Abbott Complete Major NZ Dairy Deals - en.edairynews.com
SCHD ETF Rebalance Adds Abbott, UnitedHealth as Dividend Fund Inflows Hit 4-Year High - TechStock²
Abbott Laboratories stock underperforms Monday when compared to competitors - MarketWatch
Abbott Laboratories (NYSE:ABT) Reaches New 1-Year LowShould You Sell? - marketbeat.com
Abbott, Flatiron Health Integrate Precision Oncology Tests Into Oncology EMR Platform - Clinical Lab Products
Abbott Laboratories stock hits 52-week low at 102.39 USD - Investing.com
Abbott Laboratories stock hits 52-week low at 102.39 USD By Investing.com - Investing.com Australia
Abbott integrates cancer tests into Flatiron’s EMR platform By Investing.com - in.investing.com
Abbott integrates cancer tests into Flatiron’s EMR platform - Investing.com
Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform - MarketScreener
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
0.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):